Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOURLIGHT-3: atirmociclib + letrozole versus investigator-choice CDK4/6 inhibitor + letrozole in first-line HR-positive/HER2-negative advanced or metastatic breast cancer
MOH_2025-01-09_013842Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atirmociclib in breast cancer (2 arms), sponsored by Pfizer. Started Dec 2024; status: recruiting.
02
Drugs
atirmociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2025-01-09_013842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-01-09_013842.